| |
|
|
|
Cytomx Thera  
|
|
5.23 0.17 (0.03%) |
09-17 16:00 |
|
Open: |
5.1 |
Pre close: |
5.06 |
Target:
|
6.26 
|
|
High: |
5.36 |
Low: |
5 |
Resistance:
|
5.36
6.26
|
|
Volume: |
2,058,431 |
Market Cap: |
341M |
Support:
|
4.69
4.28
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.11
|
MACD |
MACD(12,26):
|
-0.04 |
|
MA(20): |
5.08 |
Signal(12,26,9): |
-0.07 |
|
MA(100): |
6.41  |
Stochastic Oscillator |
%K(14,3):
|
47.34 |
|
MA(250): |
7.09 |
%D(3): |
44.19 |
|
Average Volume(K) |
3-Month: |
2777750
|
52-Week |
High:
|
10.05 |
|
10-Days: |
822491 |
Low: |
4.28 |
|
RSI |
RSI(14):
|
52.33 |
Change(%): |
-24.6 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.220 |
Return on Equity (ttm) |
-56.2 |
Shares Out. (M) |
65.01 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-8.8 |
Shares Float (M) |
53.88 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
0.00 |
% Held by Insiders |
1.15 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
-67.8 |
% Held by Institutions |
82.05 |
|
Forward EPS |
-2.260 |
Gross Profit (p.s.) |
1.544 |
Shares Short (K) |
6640 |
|
Book Value (p.s.) |
2.250 |
EBITDA (p.s.) |
-0.905 |
P/E |
-4.29 |
|
Sales Per Share |
1.027 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.32 |
|
Profit Margin |
-90.87 |
Operating Cash Flow
(M) |
25.06 |
P/S |
5.09 |
|
Operating Margin |
-92.06 |
Levered Free Cash Flow
(M) |
113.36 |
P/CF |
13.57 |
|
|
|
|
|
|
